BiotechTube

SPIKEVAX Bivalent

PreclinicalRecruiting
2 views this week 0 watching
0
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SARS-CoV-2

Conditions

SARS-CoV-2

Trial Timeline

Mar 10, 2023 → Dec 10, 2028

NCT ID
NCT06333704

About SPIKEVAX Bivalent

SPIKEVAX Bivalent is a preclinical stage product being developed by Moderna for SARS-CoV-2. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06333704. Target conditions include SARS-CoV-2.

What happened to similar drugs?

4 of 20 similar drugs in SARS-CoV-2 were approved

Approved (4) Terminated (1) Active (16)
✅mRNA-1273 Variant-containing FormulationModernaApproved
✅mRNA-1273ModernaApproved
✅AZD1222AstraZenecaApproved
✅BNT162b2PfizerApproved
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1083ModernaPhase 3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06333704PreclinicalRecruiting

Competing Products

20 competing products in SARS-CoV-2

See all competitors
ProductCompanyStageHype Score
mRNA-1010ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1273ModernaPhase 1
0
mRNA-1283ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1083 Composition 1 Dose A Lot AModernaPhase 2
0
mRNA-1273.214ModernaPhase 2
0
SPIKEVAXModernaPreclinical
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1083.1ModernaPhase 2
0
mRNA-1083ModernaPhase 3
0
mRNA-1273ModernaPhase 2
0
mRNA-1073ModernaPhase 2
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1273.211ModernaPhase 3
0
SPIKEVAX (mRNA-1273)ModernaPreclinical
0
mRNA-1083ModernaPhase 2
0